NASDAQ:SGEN Seagen Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Seagen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $179.33 +5.33 (+3.06%) (As of 06/24/2022 04:00 PM ET) Add Compare Share Today's Range$173.54▼$179.9650-Day Range$108.81▼$179.3352-Week Range$105.43▼$192.79Volume3.59 million shsAverage Volume1.25 million shsMarket Capitalization$33.01 billionP/E RatioN/ADividend YieldN/APrice Target$164.55 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive SGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Seagen and its competitors with MarketBeat's FREE daily newsletter. Email Address SGEN Stock Forecast (MarketRank)Overall MarketRank™2.30 out of 5 starsMedical Sector275th out of 1,418 stocksBiological Products, Except Diagnostic Industry42nd out of 216 stocksAnalyst Opinion: 2.3Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 4.2Valuation: 0.6 5 -4 -3 -2 -1 - 2.3 Analyst's Opinion Consensus RatingSeagen has received a consensus rating of Moderate Buy. The company's average rating score is 2.64, and is based on 7 buy ratings, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $164.92, Seagen has a forecasted downside of 8.0% from its current price of $179.33.Amount of Analyst CoverageSeagen has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 4.4 Community Rank Outperform VotesSeagen has received 722 “outperform” votes. (Add your “outperform” vote.)Underperform VotesSeagen has received 365 “underperform” votes. (Add your “underperform” vote.)Community SentimentSeagen has received 66.42% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Seagen and other stocks. Vote “Outperform” if you believe SGEN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SGEN will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldSeagen does not currently pay a dividend.Dividend GrowthSeagen does not have a long track record of dividend growth. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Seagen insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,516,752.00 in company stock.Percentage Held by Insiders27.30% of the stock of Seagen is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions90.37% of the stock of Seagen is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Seagen are expected to grow in the coming year, from ($3.50) to ($1.41) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Seagen is -47.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Seagen is -47.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSeagen has a P/B Ratio of 10.70. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Seagen (NASDAQ:SGEN)Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.Read More SGEN Stock News HeadlinesJune 24, 2022 | benzinga.comSeagen shares are trading higher following a WSJ report suggesting Merck is pushing forward with a potent - BenzingaJune 24, 2022 | reuters.comRoche sceptical about investing more in 'guided-missile' ADC cancer drugs - Reuters.comJune 24, 2022 | benzinga.comBMO Capital Initiates Coverage On Seagen with Market Perform Rating, Announces Price Target of $169 - Ben - BenzingaJune 24, 2022 | cnbc.comStocks making the biggest moves premarket: CarMax, FedEx, Seagen and more - CNBCJune 24, 2022 | americanbankingnews.comEquities Analysts Offer Predictions for Seagen Inc.'s FY2026 Earnings (NASDAQ:SGEN)June 23, 2022 | seekingalpha.comMerck said to move forward with possible Seagen deal - Seeking AlphaJune 23, 2022 | wsj.comMerck Pushes Forward With Potential Deal for Seagen - WSJ - The Wall Street JournalJune 23, 2022 | finance.yahoo.comThe Worldwide Combination Cancer Immunotherapy Industry is Expected to Surpass $15 Billion by 2028 - Yahoo FinanceJune 21, 2022 | seekingalpha.comSGEN stock draws Street high target at Oppenheimer on M&A prospects (NASDAQ:SGEN) - Seeking AlphaJune 21, 2022 | benzinga.comOppenheimer Maintains Outperform on Seagen, Raises Price Target to $208 - Benzinga - BenzingaJune 21, 2022 | investors.comSeagen Inc Earns Relative Strength Rating Upgrade - Investor's Business DailyJune 20, 2022 | finance.yahoo.comSeattle Genetics (SGEN) Moves 12.7% Higher: Will This Strength Last?June 19, 2022 | americanbankingnews.comSeagen (NASDAQ:SGEN) Sees Large Volume IncreaseSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:SGEN CUSIP81257810 CIK1060736 Webwww.seattlegenetics.com Phone(425) 527-4000Fax425-527-4001Employees2,675Year Founded1998Company Calendar Last Earnings4/28/2022Today6/24/2022Next Earnings (Estimated)8/04/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$164.92 High Stock Price Forecast$208.00 Low Stock Price Forecast$132.00 Forecasted Upside/Downside-8.2%Consensus RatingModerate Buy Rating Score (0-4)2.63636363636364 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($3.770010) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-674.47 million Net Margins-41.32% Pretax Margin-41.32% Return on Equity-21.86% Return on Assets-18.07% Debt Debt-to-Equity RatioN/A Current Ratio5.22 Quick Ratio4.70 Sales & Book Value Annual Sales$1.57 billion Price / Sales20.97 Cash FlowN/A Price / Cash FlowN/A Book Value$16.76 per share Price / Book10.70Miscellaneous Outstanding Shares184,076,000Free Float133,823,000Market Cap$33.01 billion OptionableOptionable Beta0.85 Social Links Seagen Frequently Asked Questions Should I buy or sell Seagen stock right now? 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Seagen in the last year. There are currently 4 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" Seagen stock. View analyst ratings for Seagen or view top-rated stocks. What is Seagen's stock price forecast for 2022? 11 equities research analysts have issued 1-year price objectives for Seagen's stock. Their SGEN stock forecasts range from $132.00 to $208.00. On average, they predict Seagen's stock price to reach $164.92 in the next year. This suggests that the stock has a possible downside of 8.0%. View analysts' price targets for Seagen or view top-rated stocks among Wall Street analysts. How has Seagen's stock performed in 2022? Seagen's stock was trading at $154.60 at the start of the year. Since then, SGEN stock has increased by 16.0% and is now trading at $179.33. View the best growth stocks for 2022 here. When is Seagen's next earnings date? Seagen is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022. View our earnings forecast for Seagen. How were Seagen's earnings last quarter? Seagen Inc. (NASDAQ:SGEN) released its quarterly earnings results on Thursday, April, 28th. The biotechnology company reported ($0.74) EPS for the quarter, topping the consensus estimate of ($0.98) by $0.24. The biotechnology company earned $426.50 million during the quarter, compared to the consensus estimate of $401.75 million. Seagen had a negative trailing twelve-month return on equity of 21.86% and a negative net margin of 41.32%. The firm's revenue for the quarter was up 28.5% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.67) earnings per share. View Seagen's earnings history. What guidance has Seagen issued on next quarter's earnings? Seagen updated its FY 2022 earnings guidance on Monday, May, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.67 billion-$1.75 billion, compared to the consensus revenue estimate of $1.78 billion. Who are Seagen's key executives? Seagen's management team includes the following people: Dr. Roger D. Dansey M.D., Chief Medical Officer & Interim CEO (Age 66, Pay $1.53M) (LinkedIn Profile)Dr. Clay B. Siegall Ph.D., Co-Founder, Chairman, Pres & CEO (Leave of Absence) (Age 61, Pay $3.09M)Mr. Todd E. Simpson, Chief Financial Officer (Age 61, Pay $1.17M)Ms. Jean I. Liu J.D., M.S., Chief Legal Officer (Age 54, Pay $1.11M) (LinkedIn Profile)Mr. Charles R. Romp, Exec. VP of Commercial U.S. (Age 54, Pay $1.02M) (LinkedIn Profile)Dr. Vaughn B. Himes Ph.D., Chief Technical Officer (Age 61)Peggy Pinkston, Sr. VP of Investor RelationsMr. David Caouette, VP of Corp. CommunicationsMs. Natasha A. Hernday, Exec. VP of Corp. Devel. & Alliance Management (Age 50)Mr. Matt Skelton, VP of Marketing What is Clay B. Siegall's approval rating as Seagen's CEO? 107 employees have rated Seagen CEO Clay B. Siegall on Glassdoor.com. Clay B. Siegall has an approval rating of 99% among Seagen's employees. This puts Clay B. Siegall in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. Who are some of Seagen's key competitors? Some companies that are related to Seagen include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), Incyte (INCY), BioMarin Pharmaceutical (BMRN), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Repligen (RGEN), Exact Sciences (EXAS), Exelixis (EXEL), Halozyme Therapeutics (HALO) and Ionis Pharmaceuticals (IONS). View all of SGEN's competitors. What other stocks do shareholders of Seagen own? Based on aggregate information from My MarketBeat watchlists, some companies that other Seagen investors own include NVIDIA (NVDA), AbbVie (ABBV), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Salesforce (CRM), QUALCOMM (QCOM), Tesla (TSLA), Micron Technology (MU), Netflix (NFLX) and Alibaba Group (BABA). What is Seagen's stock symbol? Seagen trades on the NASDAQ under the ticker symbol "SGEN." Who are Seagen's major shareholders? Seagen's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Capital International Investors (8.40%), BlackRock Inc. (7.44%), Wellington Management Group LLP (6.78%), Vanguard Group Inc. (6.67%), Primecap Management Co. CA (2.51%) and State Street Corp (1.92%). Company insiders that own Seagen stock include Bros Advisors Lp Baker, Charles R Romp, Charles R Romp, Clay B Siegall, Clay B Siegall, Daniel G Welch, Daniel G Welch, David W Gryska, David W Gryska, Jean I Liu, Jean I Liu, Lip Bu Tan, Marc E Lippman, Morgan E Obrien, Roger D Dansey, Roger D Dansey, Srinivas Akkaraju, Todd E Simpson, Todd E Simpson, Vaughn B Himes and Vaughn B Himes. View institutional ownership trends for Seagen. Which institutional investors are selling Seagen stock? SGEN stock was sold by a variety of institutional investors in the last quarter, including ANTIPODES PARTNERS Ltd, Bank of America Corp DE, Mirae Asset Global Investments Co. Ltd., Mirae Asset Global Investments Co. Ltd., TD Asset Management Inc., UBS Group AG, First Trust Advisors LP, and Tobam. Company insiders that have sold Seagen company stock in the last two years include Bros Advisors Lp Baker, Charles R Romp, Clay B Siegall, Daniel G Welch, David W Gryska, Jean I Liu, Morgan E Obrien, Roger D Dansey, Todd E Simpson, and Vaughn B Himes. View insider buying and selling activity for Seagen or view top insider-selling stocks. Which institutional investors are buying Seagen stock? SGEN stock was bought by a variety of institutional investors in the last quarter, including Capital International Investors, Wellington Management Group LLP, Woodline Partners LP, BlackRock Inc., Capital Group Private Client Services Inc., Eagle Health Investments LP, Artal Group S.A., and Vanguard Group Inc.. View insider buying and selling activity for Seagen or or view top insider-buying stocks. How do I buy shares of Seagen? Shares of SGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Seagen's stock price today? One share of SGEN stock can currently be purchased for approximately $179.33. How much money does Seagen make? Seagen (NASDAQ:SGEN) has a market capitalization of $33.01 billion and generates $1.57 billion in revenue each year. The biotechnology company earns $-674.47 million in net income (profit) each year or ($3.770010) on an earnings per share basis. How many employees does Seagen have? Seagen employs 2,675 workers across the globe. Does Seagen have any subsidiaries? The following companies are subsidiares of Seagen: Cascadian Therapeutics.Read More When was Seagen founded? Seagen was founded in 1998. How can I contact Seagen? Seagen's mailing address is 21823 30TH DRIVE SE SUITE, BOTHELL WA, 98021. The official website for Seagen is www.seattlegenetics.com. The biotechnology company can be reached via phone at (425) 527-4000, via email at [email protected], or via fax at 425-527-4001. This page (NASDAQ:SGEN) was last updated on 6/25/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here